Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 3;13(8):e072094.
doi: 10.1136/bmjopen-2023-072094.

Multicohort cross-sectional study of cognitive and behavioural digital biomarkers in neurodegeneration: the Living Lab Study protocol

Mark Crook-Rumsey  1   2 , Sarah J C Daniels  2   3 , Subati Abulikemu  2   3 , Helen Lai  2   3 , Adrien Rapeaux  2   4 , Charalambos Hadjipanayi  2   4 , Eyal Soreq  2   3 , Lucia M Li  2   3 , James Bashford  5 , Julian Jeyasingh-Jacob  2   3 , Dragos C Gruia  2   3 , Damion Lambert  2   6 , Rimona Weil  7 , Adam Hampshire  2   3 , David J Sharp  2   3 , Shlomi Haar  8   3
Affiliations

Multicohort cross-sectional study of cognitive and behavioural digital biomarkers in neurodegeneration: the Living Lab Study protocol

Mark Crook-Rumsey et al. BMJ Open. .

Abstract

Introduction and aims: Digital biomarkers can provide a cost-effective, objective and robust measure for neurological disease progression, changes in care needs and the effect of interventions. Motor function, physiology and behaviour can provide informative measures of neurological conditions and neurodegenerative decline. New digital technologies present an opportunity to provide remote, high-frequency monitoring of patients from within their homes. The purpose of the living lab study is to develop novel digital biomarkers of functional impairment in those living with neurodegenerative disease (NDD) and neurological conditions.

Methods and analysis: The Living Lab study is a cross-sectional observational study of cognition and behaviour in people living with NDDs and other, non-degenerative neurological conditions. Patients (n≥25 for each patient group) with dementia, Parkinson's disease, amyotrophic lateral sclerosis, mild cognitive impairment, traumatic brain injury and stroke along with controls (n≥60) will be pragmatically recruited. Patients will carry out activities of daily living and functional assessments within the Living Lab. The Living Lab is an apartment-laboratory containing a functional kitchen, bathroom, bed and living area to provide a controlled environment to develop novel digital biomarkers. The Living Lab provides an important intermediary stage between the conventional laboratory and the home. Multiple passive environmental sensors, internet-enabled medical devices, wearables and electroencephalography (EEG) will be used to characterise functional impairments of NDDs and non-NDD conditions. We will also relate these digital technology measures to clinical and cognitive outcomes.

Ethics and dissemination: Ethical approvals have been granted by the Imperial College Research Ethics Committee (reference number: 21IC6992). Results from the study will be disseminated at conferences and within peer-reviewed journals.

Keywords: dementia; neurology; neuropathology; neurophysiology; protocols & guidelines; telemedicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Living Lab layout. (A) Top view illustration of the Living Lab set-up. (B) Illustration of the physiological and wearable sensors. BP=blood pressure.
Figure 2
Figure 2
Graphical illustration of the Living Lab protocol. ACE-III=Addenbrooke’s cognitive examination; SPPB=Short Physical Performance Battery; EEG=electroencephalography.
See this image and copyright information in PMC

References

    1. Dorsey ER, Elbaz A, Nichols E. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2018;17:939–53. 10.1016/S1474-4422(18)30295-3 - DOI - PMC - PubMed
    1. Nichols E, Steinmetz JD, Vollset SE. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health 2022;7:e105–25. 10.1016/S2468-2667(21)00249-8 - DOI - PMC - PubMed
    1. Feigin VL, Nichols E, Alam T. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2019;18:459–80. 10.1016/S1474-4422(18)30499-X - DOI - PMC - PubMed
    1. Park Y, Go T-H, Hong SH, et al. Digital biomarkers in living LABS for vulnerable and susceptible individuals: an integrative literature review. Yonsei Med J 2022;63:S43–55. 10.3349/ymj.2022.63.S43 - DOI - PMC - PubMed
    1. Rezvani R, Kouchaki S, Nilforooshan R, et al. Analysing behavioural changes in people with dementia using In‐Home monitoring Technologies. Alzheimer’s & Dementia 2021;17:e052181. 10.1002/alz.052181 Available: https://onlinelibrary.wiley.com/toc/15525279/17/S11 - DOI

Publication types